Page 2 - Balance Sheet Data News Today

First quarter revenue of $1,358 million increased 15% year-over-year, led by international growth of 21%First quarter operating income of $233 million increased 26% year-over-yearFirst quarter net income of $112 million, an 8.2% margin, increased 56% year-over-yearFirst quarter adjusted EBITDA* of $336 million, a 24.7% margin and the highest in over 15 years, increased 25% and 206 basis points year-over-yearCash provided by operating activities of $131 million, and adjusted free cash flow* of $8

First Quarter 2024 Highlights Versus Prior Year Net Sales of $810 million, down 1% as reported and in constant currency Gross Margin of 48.0%, an increase of 800 basis points; Adjusted Gross...

First quarter revenue of $1,358 million increased 15% year-over-year, led by international growth of 21%First quarter operating income of $233 million increased 26% year-over-yearFirst quarter net...

First quarter revenue of $1,358 million increased 15% year-over-year, led by international growth of 21%First quarter operating income of $233 million...

Data from novel proprietary neurotropic adeno-associated virus delivery capsid, STAC-BBB, demonstrated industry-leading blood-brain barrier penetration in non-human primates following intravenous...

CRC Delivers Record Cash Flow and Free Cash Flow per Share Annual Results ...

Three Month Results Net revenue was $555.9 millionNet income was $149.3 millionAdjusted EBITDA was $268.2 million Twelve Month Results Net revenue was $2.11 billionNet...

SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

CINCINNATI--(BUSINESS WIRE)--Feb 6, 2024--